Better Therapeutics, Inc. (BTTX)

Market Cap	424.13K
Revenue (ttm)	n/a
Net Income (ttm)	-31.57M
Shares Out	54.52M
EPS (ttm)	-1.15
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	887,792
Open	0.0060
Previous Close	0.0060
Day's Range	0.0060 - 0.0119
52-Week Range	0.0050 - 1.3500
Beta	2.13
Analysts	Strong Buy
Price Target	6.00 (+77,020.82%)
Earnings Date	May 9, 2024

About BTTX

Better Therapeutics, Inc., a prescription digital therapeutics company, develops a form of cognitive behavioral therapy to address the causes of cardiometabolic diseases. The company's lead product candidate is BT-001, an investigational PDT platform to treat type 2 diabetes. It also develops software-based prescription digital therapeutics platform candidates for treating diabetes, heart disease, and other cardiometabolic conditions. In addition, the company's clinical development candidates are intended to treat cardiometabolic diseases, incl...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2015
• Employees: 54
• Stock Exchange: OTCMKTS
• Ticker Symbol: BTTX

Analyst Forecast

According to 2 analysts, the average rating for BTTX stock is "Strong Buy." The 12-month stock price forecast is $6.0, which is an increase of 77,020.82% from the latest price.

Price Target

$6.0

(77,020.82% upside)

Analyst Consensus: Strong Buy